Market Cap ₹147 Cr.
Stock P/E 0.0
P/B 3
Current Price ₹141
Book Value ₹ 46.4
Face Value 10
52W High ₹260
Dividend Yield 0%
52W Low ₹ 121
Hemant Surgical Industries Ltd is a renowned company that operates in the healthcare industry. Established with a commitment to excellence, the company specializes in manufacturing and supplying a wide range of surgical instruments and medical equipment. With a rich history spanning several years, Hemant Surgical Industries has earned a solid reputation for delivering high-quality products that meet stringent industry standards. The company prides itself on its state-of-the-art manufacturing facilities, equipped with advanced technology and a skilled workforce. Their comprehensive product portfolio includes surgical instruments for various specialties such as orthopedics, gynecology, cardiovascular, ophthalmology, and more. In addition to surgical instruments, they offer medical equipment like hospital furniture, sterilization products, and disposable items. Hemant Surgical Industries is dedicated to customer satisfaction, ensuring prompt delivery and exceptional after-sales support. They cater to both domestic and international markets, serving hospitals, clinics, and healthcare professionals worldwide. With a commitment to innovation, quality, and reliability, Hemant Surgical Industries Ltd continues to be a trusted name in the healthcare industry.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 28 | 31 | 32 | 40 | 51 | 51 | 56 | 56 | 60 | 104 | 109 | |
| Other Income | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | |
| Total Income | 29 | 31 | 32 | 40 | 52 | 51 | 56 | 57 | 61 | 106 | 111 | |
| Total Expenditure | 26 | 29 | 30 | 37 | 49 | 48 | 53 | 54 | 57 | 97 | 99 | |
| Operating Profit | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 4 | 8 | 13 | |
| Interest | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 6 | 10 | |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | |
| Profit After Tax | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 8 | |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 8 | |
| Adjusted Earnings Per Share | 1.5 | 1.5 | 2.2 | 2.6 | 2.8 | 2.9 | 3.5 | 2.7 | 3.6 | 14.4 | 10 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 5% | 25% | 16% | 15% |
| Operating Profit CAGR | 63% | 63% | 34% | 21% |
| PAT CAGR | 60% | 100% | 52% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 42% | 33% | 25% | 18% |
| ROCE Average | 45% | 31% | 24% | 19% |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 4 | 4 | 4 | 5 | 6 | 7 | 8 | 8 | 10 | 13 | 24 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 1 | 1 | 1 | 3 | 3 | 5 | 6 | 9 | 10 | 4 | 3 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 17 | 22 | 20 | 20 | 17 | 16 | 19 | 25 | 23 | 37 | 38 |
| Total Liabilities | 22 | 26 | 26 | 28 | 27 | 28 | 33 | 41 | 43 | 54 | 65 |
| Fixed Assets | 2 | 1 | 1 | 4 | 6 | 7 | 8 | 9 | 12 | 12 | 13 |
| Other Non-Current Assets | 1 | 3 | 5 | 5 | 5 | 5 | 6 | 6 | 5 | 5 | 5 |
| Total Current Assets | 19 | 22 | 20 | 18 | 16 | 16 | 19 | 26 | 26 | 38 | 47 |
| Total Assets | 22 | 26 | 26 | 28 | 27 | 28 | 33 | 41 | 43 | 54 | 65 |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 6 |
| Cash Flow from Operating Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 12 | 9 |
| Cash Flow from Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | -0 | -2 |
| Cash Flow from Financing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -8 | -4 |
| Net Cash Inflow / Outflow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2 | 4 | 3 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 6 | 8 |
| # | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 1.49 | 1.51 | 2.23 | 2.61 | 2.77 | 2.93 | 3.54 | 2.68 | 3.58 | 14.42 | 9.96 |
| CEPS(Rs) | 2.33 | 2.2 | 2.85 | 3.36 | 3.69 | 4.23 | 5.21 | 4.61 | 5.56 | 16.76 | 11.07 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 16 | 17.03 | 18.73 | 20.43 | 20.19 | 20.99 | 23.72 | 25.05 | 26.67 | 41.09 | 30.73 |
| Core EBITDA Margin(%) | 7.73 | 5.87 | 4.45 | 5.86 | 4.72 | 4.91 | 4.81 | 4.61 | 5.14 | 6.08 | 9.66 |
| EBIT Margin(%) | 7.77 | 5.91 | 5.92 | 5.99 | 4.67 | 4.64 | 4.73 | 4.26 | 5.57 | 7.48 | 11.04 |
| Pre Tax Margin(%) | 1.26 | 1.16 | 1.69 | 1.66 | 1.65 | 2.06 | 2.21 | 1.71 | 2.54 | 5.9 | 9.21 |
| PAT Margin (%) | 1.26 | 1.16 | 1.69 | 1.58 | 1.55 | 1.86 | 2.03 | 1.53 | 1.92 | 4.45 | 7.01 |
| Cash Profit Margin (%) | 1.97 | 1.69 | 2.15 | 2.04 | 2.06 | 2.68 | 2.99 | 2.63 | 2.98 | 5.18 | 7.79 |
| ROA(%) | 1.67 | 1.51 | 2.05 | 2.33 | 2.95 | 3.44 | 3.69 | 2.3 | 2.72 | 9.49 | 12.85 |
| ROE(%) | 9.72 | 9.16 | 12.5 | 13.31 | 14.89 | 14.98 | 15.82 | 11 | 13.84 | 42.56 | 41.64 |
| ROCE(%) | 14.41 | 12.92 | 13.17 | 15.66 | 14.76 | 14.51 | 15.23 | 11.64 | 14.34 | 32.89 | 44.94 |
| Receivable days | 47.56 | 55 | 58.59 | 48.44 | 46.91 | 44.25 | 34.01 | 35.39 | 29.58 | 35.11 | 54.93 |
| Inventory Days | 167.98 | 173.4 | 171.19 | 118.41 | 65.49 | 52.15 | 53.47 | 77.61 | 90.5 | 48.77 | 46.23 |
| Payable days | 84.25 | 125.72 | 148.89 | 113.68 | 76.22 | 89.69 | 95.11 | 113.77 | 108.19 | 74.6 | 101.79 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.41 | 0.34 | 0.34 | 0.29 | 0.23 | 0.18 | 0.22 | 0.21 | 0.25 | 0.06 | 0.06 |
| EV/Core EBITDA(x) | 4.83 | 5.3 | 5.3 | 4.57 | 4.39 | 3.32 | 3.78 | 3.97 | 3.77 | 0.7 | 0.49 |
| Net Sales Growth(%) | 16.27 | 10.31 | 1.55 | 24.67 | 29.96 | -1.83 | 10.11 | 0.79 | 6.53 | 73.3 | 5.39 |
| EBIT Growth(%) | -12.16 | -16.09 | 1.82 | 26.12 | 1.35 | -2.52 | 12.34 | -9.2 | 39.08 | 132.94 | 55.41 |
| PAT Growth(%) | -30.17 | 1.3 | 47.76 | 16.67 | 27.63 | 17.61 | 20.53 | -24.19 | 33.47 | 302.86 | 65.82 |
| EPS Growth(%) | -30.17 | 1.3 | 47.76 | 16.67 | 6.25 | 5.96 | 20.53 | -24.19 | 33.47 | 302.86 | -30.91 |
| Debt/Equity(x) | 2.76 | 2.47 | 2.2 | 2.25 | 1.87 | 1.33 | 1.5 | 1.76 | 1.69 | 0.74 | 0.3 |
| Current Ratio(x) | 1.1 | 1.03 | 0.99 | 0.91 | 0.9 | 0.97 | 1 | 1.05 | 1.13 | 1.02 | 1.23 |
| Quick Ratio(x) | 0.26 | 0.31 | 0.28 | 0.35 | 0.49 | 0.53 | 0.53 | 0.45 | 0.47 | 0.67 | 0.84 |
| Interest Cover(x) | 1.19 | 1.24 | 1.4 | 1.38 | 1.54 | 1.8 | 1.88 | 1.67 | 1.84 | 4.73 | 6.06 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Sep 2023 | Mar 2024 |
|---|---|---|
| Promoter | 73.56 | 73.56 |
| FII | 0.03 | 0 |
| DII | 4.26 | 1.97 |
| Public | 22.15 | 24.47 |
| Others | 0 | 0 |
| Total | 100 | 100 |
| # | Sep 2023 | Mar 2024 |
|---|---|---|
| Promoter | 0.77 | 0.77 |
| FII | 0 | 0 |
| DII | 0.04 | 0.02 |
| Public | 0.23 | 0.26 |
| Others | 0 | 0 |
| Total | 1.04 | 1.04 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Sell or Purchase Share (Tentative Price)
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
